Eledon Pharmaceuticals is developing tegoprubart, a monoclonal antibody targeting CD40 ligand to modulate immune activity in transplantation settings. Its lead efforts center on preventing kidney transplant rejection through ongoing Phase 2 clinical trials, with additional evaluation in xenotransplantation and potential uses in autoimmune and neurodegenerative diseases. The approach seeks non-depleting immunomodulation for transplant recipients and other patients.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -10.4 | — |
| Q3 2025 | 0 | — | -16.1 | — |
| Q4 2025 | 0 | — | -13.1 | — |
| Q1 2026 | 0 | — | -39 | — |
| Q2 2026 | 0 | — | -30.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: CF Bankshares Inc. (CFBK), QuickLogic Corporation (QUIK), NervGen Pharma Corp. (NGEN), Anavex Life Sciences Corp. (AVXL), EDAP TMS S.A. (FOCL), Lexeo Therapeutics, Inc. (LXEO)